ImmunityBio Q2 FY26 net loss widens to $230.4 million; revenue rises 92% YoY to $50.7 million

Reuters2026/08/04 11:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ImmunityBio posted Q2 net product revenue of $50.7 million, up 92% year-over-year and up 15% sequentially.
Net loss attributable to common stockholders widened to $230.4 million; adjusted net loss (non-GAAP) narrowed to $81.0 million.
R&D expense rose to $60.8 million; SG&A expense increased to $51.8 million.
First-half net product revenue climbed to $94.8 million, up 121% versus the prior-year period.
Cash, cash equivalents and marketable securities totaled $357.4 million; FDA set a Jan. 6, 2027 PDUFA date for an ANKTIVA sBLA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608040730BIZWIRE_USPR_____20260804_BW702957) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ImmunityBio Q2 FY26 net loss widens to $230.4 million; revenue rises 92% YoY to $50.7 million

You may also like

Crypto prices